Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

Research unit

INNOSUISSE

Project number

139.810 INNO-LS

Project title

Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Biotechnology and processing
Abstract (English)	MPC Therapeutics SA and the Institute of Oncology Research (IOR) test whether MITO-21, a mitochondrial pyruvate carrier inhibitor, can target drug-resistant B-cell lymphoma and resensitize it to existing treatments ? a new metabolic approach.